Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
|Articles|February 22, 2017
Fluoropolymer Cable Ties for Biopharmaceutical Manufacturing Withstand Gamma Sterilization
Strong-Ty PVDF cable ties from Nile Polymers do not degrade under gamma sterilization, thus preventing premature failure during use.
Nile Polymers’ Strong-Ty cable ties can be used in biopharmaceutical manufacturing. The cable ties are manufactured and packaged in a cleanroom, and the ties meet USP Class VI requirements.
The ties are made from Arkema’s Kynar Flex polyvinylidene fluoride (PVDF) polymer that uses a patented technology to make it resistant to degradation from gamma sterilization. PVDF also has high chemical resistance, abrasion resistance, resistance to direct sunlight, and resistance to accumulation of fungal growth. Because of its resistance to gamma radiation, the material has a long life and avoids the premature failures seen with cable ties made from other materials.
Source:
Related to this article
Episode 1, Part 3 of PharmTech AI Pulse Check covers why INTerpath-001's AI isn't ChatGPT and names pharma manufacturing's biggest AI governance gaps.
Michael Levy, senior vice president, Digital & Innovation, USP, explains the digital supply chain in a preview of his upcoming CPHI Milan panel presentation, The Next Phase of Pharma Supply Chains.
FDA approves tavapadon, first D1/D5 agonist, validating AbbVie's $8.7B Cerevel deal and an October five-strength oral tablet launch.
Richard Jaenisch weighs how FDA's new NAM rule could reshape preclinical testing and what CMC teams should do now, on Manufacturing Intelligence.
In a preview of their panel discussion at AAPS PharmSci 360 2026, Alfred Rumondor, PhD, AbbVie, and Swita Singh, PhD, Bristol Myers Squibb, discuss the implementation of risk-based approaches for CMC.
Merck licenses SciBrunch's preclinical KRAS G12D inhibitor for $2.13B, raising tech transfer and scale-up questions for oral cancer drug development.
Ronald Piervincenzi, USP, urges drugmakers and purchasers to act on supply chain resilience to curb drug shortages and shape better policy.